Learn about INVOKANA®, an SGLT2 inhibitor that helps lower blood sugar and risk of cardiovascular disease in adults. See full Prescribing & Safety Info. INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an INVOKANA mg once daily who have an eGFR of 60 mL/min/ m2. INVOKANA® is now the only oral diabetes treatment approved to in the INVOKANA® U.S. full Prescribing Information (PI).3 The PI also.

Author: Arashikinos Moogurr
Country: Costa Rica
Language: English (Spanish)
Genre: Love
Published (Last): 18 January 2005
Pages: 87
PDF File Size: 15.8 Mb
ePub File Size: 11.77 Mb
ISBN: 566-6-13911-180-7
Downloads: 47344
Price: Free* [*Free Regsitration Required]
Uploader: Doutaxe

Canagliflozin, tablet, 100 mg and 300 mg, Invokana® – July 2013

Is haemoglobin A 1c a step forward for diagnosing invokaa The sponsor claimed that most infections are self-diagnosed or diagnosed on clinical history, and therefore require no investigational diagnostic tests.

This list of uses in specific populations is not complete. Always keep a source of sugar, like fruit juice, hard candy, or crackers with you in case you have low blood sugar. Evaluate patients for fracture and fall risk. Patients improved with discontinuation of therapy and, in certain cases, administration of corticosteroids.

During darunavir postmarketing experience, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms DRESSand acute generalized exanthematous pustulosis have been reported.

Indication and Important Safety Information | Janssen CarePath

Cardiomyopathy, including cardiac failure, congestive heart failure, ejection fraction decreased, diastolic dysfunction, or right ventricular dysfunction can occur. Invokana is usually added on to other diabetes treatmentssuch as metformin, sulfonylureas, or insulin, as an “adjunct”, when a patient no longer responds, or if the blood sugar level is too high at the outset. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents.


Please see full Prescribing Information. But if it is almost time for next dose, skip the missed dose and take Invokana at your regularly scheduled time. The following was noted from the Phase III trials:. The HbA1c must be no more than 4 months old at the time treatment with a sodium glucose co-transporter-2 inhibitor, a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

RPLS can present with headache, seizures, confusion, and visual disturbances. Add-on combination therapy – Combination therapy with other anti-hyperglycaemic agents including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control 4.

Like most other medicines, Invokana has important drug interactions you should be aware of. New Drug Approved for Type 2 Diabetes. The most common Invokana side effects include: One case of reversible posterior leukoencephalopathy syndrome RPLS was observed in clinical studies of psoriasis and psoriatic arthritis. The PBAC pii that treatment choice may be influenced by patient inokana to use injectable formulations, and that this was consistent with views expressed in correspondence the PBAC received from diabetes organisations.

Indication and Important Safety Information

In particular, the PBAC noted utilisation patterns indicating prescribing of some agents outside PBS restrictions, and considered this to be a matter of concern. Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: In patients with chronic kidney disease, also assess serum phosphorus.


Clinical Place for the Proposed Therapy Type 2 diabetes is a metabolic disorder characterised by hyperglycaemia resulting from resistance to the action of insulin, insufficient insulin secretion or both. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

Invokana Insights: 10 Drug-Specific Facts You Should Know

It considers submissions in this context. There were no Grade 3 or 4 adverse reactions. The submission also considered canagliflozin mg equivalent to sitagliptin 50 mg.

Canagliflozin was TGA registered on 12 September for treatment of adults with type 2 diabetes mellitus, invokzna an adjunct to diet and exercise, to improve glycaemic control as:. Exercise caution and monitor patients with heart failure.

View all slides as one page. Acute kidney injury, requiring hospitalization and dialysis, has been reported; some reports involved patients younger than 65 years of age. The availability of new classes of treatments, such as sodium glucose cotransporter-2 SGLT-2 inhibitors, would be expected to further influence future treatment algorithms.

Usually, most patients will start at the mg dose, but your dose may go invokanaa.

Monitor patients during infusion and if a serious reaction occurs, discontinue infusion. If a strong CYP3A inhibitor for short-term use i.